Besivance Receives Bacterial Conjunctivitis Indication
The FDA has granted additional labeling indications
for besifloxacin ophthalmic suspension 0.6%
(Besivance; Bausch + Lomb) eye drop.
Included in the additional indications is the treatment
of bacterial conjunctivitis infections caused by
susceptible isolates of emPseudomonas aeruginosa/em, a rare
but potentially vir...